NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/02/2023
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Snapshot rápido
ST13
US500000090144485Classe
Pedido
Registro
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Fundamento do pedido
Primeiro uso
Primeiro uso no comércio
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Descrição da marca
The mark consists of the wording "ZEAL&" with each letter appearing in white, in a blue circle, an overlapped grey circle, an overlapped yellow circle, an overlapped turquoise circle, a red circle, from left to right, with the grey wording "ZEALAND PHARMA" written below.
Titulares
Representantes
Shannon Marie McKeon DYKEMA GOSSETT PLLC
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
(Based on 44(e)) Pharmaceutical preparations for the treatment of diabetes, obesity and gastrointestinal diseases; synthetic peptides for pharmaceuticals purposes for the treatment of diabetes, obesity and gastrointestinal diseases; pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans, namely, pharmaceutical preparations for treating endocrine disorders, immunity disorders, nutritional and metabolic diseases, such as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune system, such as complement inhibitors; apparatus and instruments containing pharmaceutical preparations, substances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes containing insulin or glucagon or analogues of those
Classe 10
(Based on Use in Commerce) Medical apparatus and instruments, namely, diabetes management devices, infusion and injection devices, infusion pumps, infusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; blood glucose monitors for medical purposes; glucose monitor accessories, namely, transmitters, receivers, and medical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods; wearable health devices for insulin monitoring
Classe 16
(Based on Use in Commerce) printed pharmaceutical information leaflets in the field of diabetes, obesity and gastrointestinal diseases; printed publications, namely, books, magazines, periodicals and manuals, all in the field of diabetes, obesity and gastrointestinal diseases; printed instructional or teaching matter in the field of diabetes, obesity and gastrointestinal diseases; printed instructional and teaching materials about diagnosing and treatment of diabetes, obesity and gastrointestinal diseases; printed guidelines for diagnosing and treatment of diabetes, obesity and gastrointestinal diseases
Classe 35
(Based on 44(e)) Marketing services; customer relationship management; business administrative services for medical referrals; patient relationship management services; business administration of pharmacy and pharmaceutical benefit plans
Classe 41
(Based on Use in Commerce) Publication of articles and scientific text and posters featuring the results of clinical trials for pharmaceutical preparations related to diabetes, obesity and gastrointestinal diseases; providing educational seminars, educational exhibitions, conferences and training courses, all in the field of diabetes, obesity and gastrointestinal diseases; educational seminars, educational exhibitions, conferences and instructional services relating to medical treatments in the field of diabetes, obesity and gastrointestinal diseases; educational services, namely, organizing and conducting educational programs, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity and gastrointestinal diseases
Classe 42
(Based on 44(e)) Scientific and technological services, namely, research and design in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetes, obesity and gastrointestinal diseases; providing websites featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity and gastrointestinal diseases; computer services, namely, providing a website featuring technology that enables users to obtain data concerning medical analysis and management of diabetes, obesity and gastrointestinal diseases
Classe 44
(Based on 44(e)) Medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseases, illnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; clinical trials; medical consulting services, namely, providing patient adherence programs to patients suffering from diabetes, obesity or gastrointestinal diseases; providing web-based on-line portals that provide a patient adherence program to patients suffering from diabetes, obesity or gastrointestinal diseases; medical information services, namely, providing information relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical advisory services, namely, providing advisory services relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical information and advice in relation to treatment planning, including information and advice provided via the Internet, databases and application software; consultancy services relating to the aforesaid
Classe 45
(Based on 44(e)) Licensing of patent and intellectual property rights arising from medical and pharmaceutical research and development activities; licensing of proprietary intellectual property
Histórico de despachos e eventos da marca no USPTO.
52 publicações encontradas
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/02/2023
REGISTERED-PRINCIPAL REGISTER
21/02/2023
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
14/01/2023
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
13/01/2023
ASSIGNED TO EXAMINER
17/12/2022
STATEMENT OF USE PROCESSING COMPLETE
15/11/2022
CASE ASSIGNED TO INTENT TO USE PARALEGAL
15/11/2022
USE AMENDMENT FILED
27/10/2022
TEAS STATEMENT OF USE RECEIVED
27/10/2022
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
23/06/2022
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/06/2022
SOU EXTENSION 1 GRANTED
07/06/2022
SOU EXTENSION 1 FILED
07/06/2022
SOU TEAS EXTENSION RECEIVED
07/06/2022
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
04/02/2022
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
14/12/2021
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/10/2021
PUBLISHED FOR OPPOSITION
19/10/2021
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/09/2021
LAW OFFICE PUBLICATION REVIEW COMPLETED
13/09/2021
ASSIGNED TO LIE
12/09/2021
APPROVED FOR PUB - PRINCIPAL REGISTER
11/09/2021
EXAMINER'S AMENDMENT ENTERED
11/09/2021
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/09/2021
EXAMINERS AMENDMENT E-MAILED
11/09/2021
EXAMINERS AMENDMENT -WRITTEN
11/09/2021
PREVIOUS ALLOWANCE COUNT WITHDRAWN
09/09/2021
WITHDRAWN FROM PUB - OG REVIEW QUERY
07/09/2021
APPROVED FOR PUB - PRINCIPAL REGISTER
24/08/2021
EXAMINER'S AMENDMENT ENTERED
24/08/2021
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
24/08/2021
EXAMINERS AMENDMENT E-MAILED
24/08/2021
EXAMINERS AMENDMENT -WRITTEN
24/08/2021
NOTIFICATION OF FINAL REFUSAL EMAILED
05/08/2021
FINAL REFUSAL E-MAILED
05/08/2021
FINAL REFUSAL WRITTEN
05/08/2021
TEAS/EMAIL CORRESPONDENCE ENTERED
03/08/2021
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/08/2021
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/08/2021
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/07/2021
NON-FINAL ACTION E-MAILED
27/07/2021
NON-FINAL ACTION WRITTEN
27/07/2021
TEAS/EMAIL CORRESPONDENCE ENTERED
25/06/2021
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/06/2021
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/06/2021
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/01/2021
NON-FINAL ACTION E-MAILED
07/01/2021
NON-FINAL ACTION WRITTEN
07/01/2021
ASSIGNED TO EXAMINER
30/12/2020
NOTICE OF DESIGN SEARCH CODE E-MAILED
02/10/2020
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/10/2020
NEW APPLICATION ENTERED
01/09/2020
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.